Australia-based gut health biotech company Microba has launched a research and development program to develop gut microbiome derived therapeutics for IBD. Microba has identified distinct differences in the gut microbiome of healthy individuals and those with IBD. Using deep learning artificial intelligence, their scientists are now able to predict IBD in patients from microbiome data alone with 86% accuracy. The program aims to create novel therapeutics that will rapidly induce and maintain remission in those with IBD. Microba launched the program at BIO in Philadelphia with the Queensland Minister for Innovation, The Hon. Kate Jones in June. | http://bit.ly/2T5B37F